Biotech Values

[DewDiligence]

ADHD is not only a medical condition, but also a stock ticker:

http://finance.yahoo.com/news/alcobra-ltd-prices-initial-public-003433197.html

Alcobra Ltd., an emerging biopharmaceutical company primarily focused on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder, today announced the pricing of its initial public offering of 3,125,000 ordinary shares at an initial public offering price of $8.00 per share. The gross proceeds to Alcobra from the initial public offering are expected to be $25,000,000 [8 x 3.125 = 25, duh]… The ordinary shares are scheduled to begin trading on The NASDAQ Capital Market on May 22, 2013 under the symbol "ADHD."